Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT05067621 on ClinicalTrials.gov · last registry update 2026-04-15

Closed to new participants; the 60 already enrolled are still being followed. Due to report December 2026, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Change in Oral Disposition Index (oDI). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 17 July 2023 — 3 years so far. semaglutide is approved in the US, but not for mash nafld and prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: ACTIVE_NOT_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Yale University
Sponsor type: Other
Enrollment: 60
Started: 2023-07-17
Primary completion: 2026-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Oral Disposition Index (oDI)

Conditions studied

Type 2 Diabetes Mellitus · Impaired Glucose Tolerance · Non-Alcoholic Fatty Liver Disease · Obesity, Childhood

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.